Future prospective studies incorporating detailed pharmacological records (to account for statin use) and nutritional status indicators (e.g., albumin, BMI) are necessary to validate the mechanism behind the protective dyslipidemia paradox observed in this cohort. This evidence concerns the gene ALB and metabolic syndrome.